NASDAQ:HOLX - Hologic Stock Price, Forecast & News

$54.32

+0.10 (+0.18 %)

(As of 01/19/2020 04:00 PM ET)

Add

Compare

Today's Range

$54.20

Now: $54.32▼

$54.73

50-Day Range

$51.32

MA: $52.54▼

$54.32

52-Week Range

$42.61

Now: $54.32▼

$54.73

Volume1.67 million shs

Average Volume1.51 million shs

Market Capitalization$14.57 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.76

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry X-ray apparatus & tubes

Sub-IndustryHealth Care Equipment

SectorMedical

Current SymbolNASDAQ:HOLX

Previous Symbol

CUSIP43644010

CIK859737

Webhttp://www.hologic.com/

Phone508-263-2900

Debt

Debt-to-Equity Ratio1.32

Current Ratio1.68

Quick Ratio1.26

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio20.73

P/E Growth2.38

Sales & Book Value

Annual Sales$3.37 billion

Price / Sales4.33

Cash Flow$4.21 per share

Price / Cash Flow12.91

Book Value$7.91 per share

Price / Book6.87

Profitability

EPS (Most Recent Fiscal Year)$2.43

Net Income$-203,600,000.00

Net Margins-1.19%

Return on Equity29.67%

Return on Assets9.98%

Miscellaneous

Employees6,478

Outstanding Shares268,140,000

Market Cap$14.57 billion

Next Earnings Date1/29/2020 (Confirmed)

OptionableOptionable

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

(Ad)

If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

Hologic (NASDAQ:HOLX) Frequently Asked Questions

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its earnings results on Wednesday, November, 6th. The medical equipment provider reported $0.65 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.65. The medical equipment provider had revenue of $865.80 million for the quarter, compared to analysts' expectations of $846.54 million. Hologic had a positive return on equity of 29.67% and a negative net margin of 1.19%. The business's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.58 earnings per share. View Hologic's Earnings History.

When is Hologic's next earnings date?

Hologic is scheduled to release their next quarterly earnings announcement on Wednesday, January 29th 2020. View Earnings Estimates for Hologic.

How can I listen to Hologic's earnings call?

Hologic will be holding an earnings conference call on Wednesday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY19 earnings guidance on Wednesday, November, 6th. The company provided earnings per share guidance of $2.60-2.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.44. The company issued revenue guidance of $3.4-3.5 billion, compared to the consensus revenue estimate of $3.35 billion.

What price target have analysts set for HOLX?

13 equities research analysts have issued 12 month price targets for Hologic's stock. Their forecasts range from $50.00 to $62.00. On average, they anticipate Hologic's stock price to reach $55.50 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Price Targets for Hologic.

What is the consensus analysts' recommendation for Hologic?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

1. According to Zacks Investment Research, "Hologic exited the third quarter of fiscal 2019 on a solid note. The company registered strong top-line growth driven by solid increase in core businesses like Breast Health and Molecular Diagnostics. We are also upbeat about the recent launches like Aptima BV and Aptima CV/TV assays in the United States, the Trident HD specimen radiography system in the United States, Europe and Canada, and ThinPrep Genesis processor for cytology slide and molecular test preparation in Europe. Hologic has outperformed its industry over the past three months. On the flip side, foreign exchange headwind got intense during the quarter. Further, both the company’s margins contracted in the quarter under review. This apart volume environment for testing laboratories and utilization weaknesses are looming headwinds." (8/16/2019)
2. Canaccord Genuity analysts commented, "We look for greater evidence for Hologic to find a solution to its declining gross margins and we need more time to get confident that Cynosure has bottomed. Nevertheless, near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide. That said, its FY’19 raised" revenue is less than the FQ3 $17M beat (FX headwinds being one factor), a consistent trend of setting a low bar for the next reporting quarter and essentially not raising its underlying baseline guide. We reiterate our HOLD, PT to $52. FQ3 beat. (+3.4% rep, +4.7% FXN) exceeded our/Street’s $835ME and adj." (8/1/2019)
3. Needham & Company LLC analysts commented, "FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast tomosynthesis (DBT) units increased by 92 during June which represents a 30.8% Y/Y decrease. DBT unit penetration increased to 37.3% from 37.0% last month and facility penetration increased to 62.1% from 61.4% last month. More importantly, DBT units placements were up 2.7% quarter-to-date (QTD) in 2Q19 vs. 2Q18. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA spreadsheet." (7/10/2019)

Has Hologic been receiving favorable news coverage?

News articles about HOLX stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Hologic earned a news impact score of -1.5 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Hologic.

Are investors shorting Hologic?

Hologic saw a decline in short interest in December. As of December 31st, there was short interest totalling 4,380,000 shares, a decline of 21.5% from the December 15th total of 5,580,000 shares. Based on an average daily volume of 2,190,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.7% of the shares of the stock are short sold. View Hologic's Current Options Chain.

Who are some of Hologic's key competitors?

Some companies that are related to Hologic include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Alibaba Group (BABA), Bank of America (BAC), salesforce.com (CRM), AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ) and Micron Technology (MU).

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
Mr. John M. Griffin, Gen. Counsel (Age 58)
Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)

Who are Hologic's major shareholders?

Hologic's stock is owned by many different of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.29%), Assenagon Asset Management S.A. (0.29%), Gateway Investment Advisers LLC (0.13%), PGGM Investments (0.06%), State of Alaska Department of Revenue (0.06%) and McGuire Investment Group LLC (0.03%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Charles J Dockendorff, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Namal Nawana, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View Institutional Ownership Trends for Hologic.

Which institutional investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue, Gateway Investment Advisers LLC, Nisa Investment Advisors LLC, McGuire Investment Group LLC, Webster Bank N. A., IFM Investors Pty Ltd and Raymond James Trust N.A.. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View Insider Buying and Selling for Hologic.

Which institutional investors are buying Hologic stock?

HOLX stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., PGGM Investments, Wedge Capital Management L L P NC, Sciencast Management LP, Zeke Capital Advisors LLC, AE Wealth Management LLC and Cerebellum GP LLC. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $54.32.

How big of a company is Hologic?

Hologic has a market capitalization of $14.57 billion and generates $3.37 billion in revenue each year. The medical equipment provider earns $-203,600,000.00 in net income (profit) each year or $2.43 on an earnings per share basis. Hologic employs 6,478 workers across the globe.View Additional Information About Hologic.

What is Hologic's official website?

The official website for Hologic is http://www.hologic.com/.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

MarketBeat Community Rating for Hologic (NASDAQ HOLX)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		738 (Vote Outperform)
Underperform Votes:		589 (Vote Underperform)
Total Votes:		1,327

MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe HOLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOLX will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Why is the ex-dividend date different from the record date?

Your Ultimate Investing Toolkit

Just $1.00 for your first month.